Anisa Scott - Publications

Pharmacology University of Virginia, Charlottesville, VA 

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, Dubois LG, Freed TA, Silinski MA, Barta TE, Hughes PF, et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chemistry & Biology. 17: 686-94. PMID 20659681 DOI: 10.1016/J.Chembiol.2010.04.015  0.497
2010 Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. The Journal of Pharmacology and Experimental Therapeutics. 332: 849-57. PMID 19934398 DOI: 10.1124/Jpet.109.158436  0.479
2009 Rice JW, Veal JM, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P, Hall S. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncology Research. 18: 229-42. PMID 20225761 DOI: 10.3727/096504009X12596189659240  0.66
2009 Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, Silinski MA, Hu M, Partridge JM, Scott A, DuBois LG, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. Journal of Medicinal Chemistry. 52: 4288-305. PMID 19552433 DOI: 10.1021/Jm900230J  0.703
2008 Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 240-8. PMID 18172276 DOI: 10.1158/1078-0432.Ccr-07-1667  0.679
2006 Barabasz A, Foley B, Otto JC, Scott A, Rice J. The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. Assay and Drug Development Technologies. 4: 153-63. PMID 16712419 DOI: 10.1089/Adt.2006.4.153  0.452
2006 Steed P, Huang H, Fadden P, Rice J, Eaves J, Barbasz A, Foley B, Partridge J, Scott A, Hall S. 545 POSTER SNX-2112: a novel, selective, potent small molecule inhibitor of Hsp90 with unique pharmacodynamic properties European Journal of Cancer Supplements. 4: 165. DOI: 10.1016/S1359-6349(06)70550-X  0.425
1995 Scott A, Haystead CMM, Haystead TAJ. Purification of a 12,020-dalton protein that enhances the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase Journal of Biological Chemistry. 270: 24540-24547. PMID 7592672 DOI: 10.1074/Jbc.270.41.24540  0.324
Show low-probability matches.